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Purpose: To evaluate the association between quantitative optical coherence tomog-
raphy angiography (OCT-A) parameters and clinical outcomes in treatment-naïve
neovascular age-related macular degeneration (nAMD) patients treated with a treat-
and-extend dosing regimen on a 12-month follow-up interval.
Methods: Observational, prospective study of consecutive patients. The treatment
protocol was based on a loading dose of three anti-vascular endothelial growth factor
(VEGF) intravitreal injections (IVI) followed by a treat-and-extend regimen. Eyes were
evaluated by swept-source OCT-A at baseline, 1 month after the loading dose and at
12months. Aquantitative analysiswas issued for fractal dimension (FD), lacunarity index
(LAC), blood flow surface area (SA), and vessel density (VD). An association of these
parameters with the anatomic response and functional responses, and IVI number at
12 months of follow-up was assessed. A level of significance α = 0.05 was considered.
Results: Sixty-four patients were included, 52 of whom (81%) completed the 12-month
study protocol. The median number of injections at 12 months was 7 (P25-P75: 6-12).
FD and SA were reduced 1 month after the loading dose of anti-VEGF (P < 0.001). The
generalized linear models using baseline FD and baseline SA achieved the best perfor-
mance in discriminating a lower treatment burden (area under the curve [AUC] = 0.78;
95% confidence interval [CI]: 0.64–0.91 and AUC= 0.76; 95%CI: 0.63–0.90, respectively).
Conclusions: Baseline OCT-A may provide useful biomarkers for the treatment burden
in nAMD.
Translational Relevance: The application of fractal dimension and automatic blood
flow area algorithms to OCT-A data can distinguish patients with distinct treatment
burdens in the first year of nAMD.
Copyright 2020 The Authors
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Introduction
Late stage age-related macular degeneration
(AMD) has been considered as the leading cause
of blindness in industrialized countries.1 In most cases,
neovascular AMD (nAMD) is characterized by the
growth of abnormal blood vessels from the choroid
through Bruch’s membrane. The natural course of the
disease is characterized by exudation, disruption of
the outer retinal architecture, and fibrosis leading to
an irreversible vision loss.2 Clinical trials have proven
that regular intravitreal injections (IVI) of vascular
endothelial growth factor (VEGF) inhibitors reduce
the exudation and slow-down the progression of the
disease.3 The burden of regular IVI dictated the need
to adapt treatment protocols following the rapid initial
functional and structural response to anti-VEGF IVI.4
In daily clinical practice, the effect of anti-VEGF
therapy is efficiently monitored with non-invasive
structural optical coherence tomography (OCT).
This follow-up relies on indirect signs of neovascular
activity, such as intraretinal fluid, subretinal fluid, or
pigment epithelial detachments.3
OCT-angiography (OCT-A) is the most recent
advance of OCT technology and provides high-
resolution images of retinal and choroidal vascular
perfusion.5 It can detect choroidal neovascularization
(CNV) with the same sensitivity as dye angiographies
and enables the evaluation of morphological features
of neovascular networks.6 Recently, some authors
have demonstrated consistent qualitative features and
immature lesions were associated with a greater rate
of small branching vessels and peripheral arcades and
hypermature lesions with a dead-tree appearance.6–8
To eliminate the subjectivity of the qualitative evalu-
ation, there has been a growing interest on quantita-
tive features of neovascular networks, and the evalu-
ation of novel imaging biomarkers for nAMD disease
activity has become a topic of increasing research inter-
est. It has been previously demonstrated that the CNV
surface area (SA)9 and vessel density (VD)10 could be
reliably measured during the follow up and that the
branching complexity and organization of the neovas-
cular network could be characterized using fractal-
based metrics, such as fractal dimension (FD)11,12 and
lacunarity (LAC).13
Changes in blood flow area following the loading
dose and during “pro re nata” treatment with anti-
VEGF have been described.7,9 These studies showed
that the blood flow area increased during the follow-up,
however they were not able to identify an association
between areamodifications and exudation. The charac-
terization of quantitative OCT-A biomarkers during a
treat and extend protocol remains to be established.
The aim of this study was to evaluate quantitative
OCT-A parameters of CNVs under a treat and extend
(TAE) dosing regimen over a twelve-month follow-
up period and to study their association with clinical
outcomes.
Material and Methods
Study Design and Setting
Prospective, observational real-life study of consec-
utive patients observed during routine clinical practice
at the Centre Ophtalmologique de l’Odeon (Paris,
France) between June 2017 and June 2019. This study
had institutional review board approval from Paris
Est University and was conducted in accordance with
the tenets of the Declaration of Helsinki (1964) and
the French legislation. All the enrolled patients gave
their written informed consent at the time of the study
recruitment.
Participants
Patients with a novel diagnosis of exudative AMD
(either type 1 or type 2 CNV) were enrolled. The
classification of CNV subtype was based on multi-
modal imaging (OCT, fluorescein angiography, and
indocyanine green angiography) and was indepen-
dently reviewed by two experienced examiners (F.C.,
C.F.). Only one eye per patient could enter the study
(in cases of bilateral disease, the first eye diagnosed
with nAMD was enrolled). Exclusion criteria were:
spherical equivalent higher than +3 or lower than -
6.0 diopters; diagnosis of glaucoma or ocular hyper-
tension; other retinal confounding diseases compli-
cated with secondary neovascularization; poor quality
images in OCT-A (signal strength index <80); evident
motion artifacts; neovascular network that exceeded
the 4.5 × 4.5 mm scanning area; multiple CNV
lesions; pigment epithelium detachment (PED) height
> 250 μm; and central geographic atrophy.
Treatment and Observation Protocol
The treatment protocol consisted in a loading
dose of 3 monthly IVI of anti-VEGF (aflibercept)
after the nAMD diagnosis followed by a TAE treat-
ment protocol. Patient follow-up visits and treat-
ments were extended by intervals of two weeks if no
signs of CNV activity were present on structural-OCT
scans. However, if any signs of neovascular activity
were detected, treatment intervals were subsequently
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shortened by a 2-week interval. Anti-VEGF treat-
ment was administered at every visit, regardless of
CNV activity. Neovascular activity was considered in
the presence of one of the following criteria: visual
acuity loss of at least five letters with structural-OCT
evidence of intraretinal and/or subretinal fluid within
the macula; macular hemorrhage; evidence of persis-
tent or increased fluid accumulation on structural OCT
after the previous injection.4
Data Collection
All patients had comprehensive medical observa-
tions scheduled according to the treatment protocol
criteria. Data were collected at the time of diagnosis
(baseline), 1 month after the loading dose (3-month
visit) and 12 months after the first IVI (12-month
visit). In each visit, the following procedures were
performed: best corrected visual acuity (BCVA) using
the Early Treatment of Diabetic Retinopathy Study
(ETDRS) visual chart, color fundus photography,
spectral domain structural OCT-B scans (Spectralis
OCT, Heidelberg Engineering Inc., Heidelberg,
Germany) and swept-source OCT-A (DRI OCT
Triton, Topcon, Tokyo, Japan). At baseline, all patients
performed two consecutive measurements of FD,
LAC, SA, and VD for repeatability analysis. The first
acquisition was used for further analysis. Pertinent
clinical characteristics were recorded for statistical
analyses.
Analysis of Structural and Clinical Outcomes
The anatomic response after the loading dose was
classified as either good response or bad response.
Because a standardized definition of good respon-
ders versus bad responders has not yet been validated,
we defined the anatomic response based on previ-
ous reports.4,14,15 A good responder was defined as
the complete resolution of the intraretinal or subreti-
nal fluid or more than 100 μm decrease of central
macular thickness 1month following the last IVI of the
loading dose. A bad responder was defined as having an
increase of central macular thickness or a decrease of
less than 100 μm in the same time point.
A good functional response was defined as a gain
in the BCVA of at least five ETDRS letters between
baseline and the 12-month visit.
A subanalysis regarding the treatment burden was
performed according to the number of IVI received
during the 12-month follow-up. Cutoff values were
established on the base of the average number of
treatments that are expected during 12 months of
TAE.16 Accordingly, regular treatment was considered
for patients with 8 or more IVI and extended treatment
was considered for patients with 7 or less injections in
the first 12 months.
A diagram of the observation protocol including
the study outcomes is available as a supplementary
Figure S1.
Image Acquisition and Analysis
Enhanced depth imaging spectral domain OCT
with a macular volume scan of 49 B-scans and a
30 degrees line scan centered on the fovea were
performed using OCT 2 and the Heyex v6.9a software
(Spectralis OCT). Optical coherence tomography
angiography images of 4.5 × 4.5mm centered on
the fovea were obtained with the swept-source DRI
OCT Triton (Topcon, Tokyo, Japan). IMAGEnet 6
version 1.25 was used to evaluate the outer retinal
layers, between the outer plexiform layer and Bruch’s
membrane, for detecting potential blood flow abnor-
malities suggestive of CNV.17 Projection artifacts were
subtracted automatically using the inbuilt algorithm.
Images were exported as tagged image file format
(TIFF). OCT-A image analysis was done using a
previously validated custom graphical user interface
built in MATLAB (v. r2018a) coding language that
enables to detect blood flow automatically.12 SA and
VD were calculated from binary images. The box
counting method starting at multiple origins was
applied to the image of the binary skeleton to estimate
FD18 and LAC19 of the vascular network, which are
global indices of morphological complexity and struc-
tural nonuniformity, respectively.20 Box sizes followed
the power of two series until a box of half image
pixel size was reached. The results were automatically
exported into a comma separated file for further analy-
sis. A composite about the image analysis protocol is
presented in Figure 1.
Statistical Analysis
An exploratory study of demographic, clinical, and
OCT-A measurements (FD, LAC, SA, and VD) was
performed. Continuous variables were presented as
mean and standard deviation (SD) or median and
interquartile range (25th-75th percentile) or range (R:
minimum:maximum), as appropriate.
To assess reliability of measurements, the intraclass
correlation coefficient (ICC) between the two consec-
utive baseline acquisitions was estimated based on a
mean-rating (k= 2), absolute-agreement, 2-waymixed-
effects model.
Intragroup serial comparisons were carried out
using the exact Wilcoxon test or sign test, as
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Figure 1. Composite exposing the image analysis protocol. (Upper left) Optical coherence tomography angiography (OCTA) 4.5 ×
4.5 mm outer retina and choriocapillaris slab showing the automatic delimitation of the choroidal neovascularization (CNV).
(Upper right) Blood flow is isolated from the background for further analysis. (Lower left) Skeletonization of the blood flow aspect
and division of the image by squares of equal sizes. (Lower right) The process is repeated by a power series of box sizes
(base = 2 ; exponent = 2); a graphic with the output of the box-counting method is displayed: N (the number of boxes needed to cover
the set) is depicted as a function of R (the size of the boxes); as the set is a fractal, we can observe a power-law relationship [N=N0 _ Rˆ(-DF)],
with DF being the fractal dimension (Kolmogorov capacity).
appropriate. Intergroup comparisons were preformed
using Mann-Whitney test.
We analyzed the association between each of
the OCTA measurements and the binary dependent
variables: treatment response after the loading dose
(good response vs. bad response to anti-VEGF),
functional response (gain in the BCVA of at least five
ETDRS letters vs the remaining patients) and treat-
ment burden (less than eight IVIs vs eight or more
IVIs). Generalized linear models (GLM)21 for binary
response were used for this purpose. Receiver operating
characteristic curves were used to evaluate the discrim-
inative ability of each model. Generally, an area under
the curve (AUC) value above 0.80 indicated a very
good discriminative ability, a value between 0.70 and
0.80 a good ability, and a value between 0.50 and 0.70
a weak discriminative ability. A P value ≤0.05 was
considered as statistically significant. Statistical analy-
ses were performed using both IBM SPSS Statistics for
windows, version 25.0 (Armonk, NY: IBM Corp.) and
R (version 3.6.0; R Foundation for Statistical Comput-
ing).
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Table 1. Demographic and Clinical Characteristics at
Baseline (n = 64)
Sex
Male, n (%) 33 (52)
Female, n (%) 31 (48)
Age, mean (SD), years 78.5 (8.1)
Eye
Right, n (%) 29 (45)
Left, n (%) 35 (55)
Type of CNV
1, n (%) 38 (59)
2, n (%) 26 (41)
Central macular thickness, mean
(SD), μm
390 (116)





During screening, 79 patients were considered eligi-
ble. From this cohort were excluded: 9 patients because
of PED detachment height superior to 250 μm; 4
patients from imaging artifacts; 1 patient because of
concurring central geographic atrophy; and 1 patient
because of high spherical equivalent. Therefore, a total
of 64 patients were considered at baseline, all of them
had CNV blood flow detectable using Swept-Source
(SS)-OCTA. From this cohort, 52 (81%) completed
the 12-month study protocol. Regarding patients that
did not complete the 12-month follow up, informa-
tion from the first medical visit and the visit after
the loading of anti-VEGF were used (clinical and
demographical characteristics are detailed in Table 1).
Regarding OCT-A parameters, FD and SA
decreased between baseline and the 3-month visit
(P < 0.001 and P = 0.006, respectively). Afterwards,
we observed a regrowth of the lesion and at the 12-
month visit the median values of OCTA parameters
were not statistically different from baseline values
(Table 2). Figure 2 represents examples of typical
active neovascularization lesions in which we can
observe the pruning effect of anti-VEGF after the
loading dose of anti-VEGF, with disappearance of
the tiny vessels along with a shrinkage of blood flow
surface area, and the regrowth of the CNV observed
at the 12-month visit. A complete characterization of
clinical and OCT-A parameters during the follow-up
is available in Supplementary Table S1.
Medians comparison and the discriminative perfor-
mance analyses of univariable models regarding each
OCT-A parameter (FD, LAC, SA, and VD) for each
outcome is summarized in Supplementary Tables S2-
S4 and Supplementary Tables S5-S7, respectively.
A good anatomic response after the loading dose
was verified in 63% (40/64) of patients. OCT-A param-
eters medians comparison did not disclose any signifi-
cant difference and none of the GLM models attained
a relevant discriminative ability.
A good functional response was present in 63%
(33/52) of patients. OCTA parameters medians
comparison did not disclose any significant differ-
ence and none of the GLM models attained a relevant
discriminative ability. The median BCVA difference
after loading dose to baseline was 7 (4-15) in patients
with a good functional response and in bad respon-
ders was -1 (-6 to 7) ETDRS letters (P = 0.001). A
GLM model using this parameter achieved a good
performance in identifying patients with a good
functional response at 12 months (AUC = 0.78; 95%
confidence interval [CI], 0.64-0.92). The odds ratio
estimate was 1.11 (95% CI, 1.04-1.21). The association
between BCVA difference after loading dose and a
good functional response at 12 months is depicted in
Figure 3.
Regarding treatment burden, the median number
of injections at 12 months was 7 (range: 6-12); 44%
(n = 23) of the patients were classified as regular
treatment. All patients had at least some response to
the drug administered, so we had no cases of switch-
ing. The median baseline FD in regular treatment was
1.40 (1.32-1.49) and in extension treatment was 1.52
(1.47-1.56) (P = 0.001). The median baseline SA in
regular treatment patients was 0.33 (0.17-0.58) and
in the extension treatment was 1.14 (0.47-2.79) (P =
0.001). GLM models using baseline FD (AUC = 0.78;
95% CI, 0.64-0.91) and baseline SA (AUC = 0.76;
95% CI, 0.63-0.90) achieved the best performance. The
odds ratio estimate of baseline FD was 0.99 (95%
CI, 0.98-0.99) and of baseline SA was 0.29 (95% CI,
0.09-0.68). The association between baseline FD and
baseline SA with treatment burden may be observed
in Figure 4. Figures 5 and 6 represent typical examples
that reflect the association between baseline FD and
baseline SA with treatment burden. We can observe
that CNVs with a higher FD or a higher SA at baseline
had a lower treatment burden (seven of less IVI) than
lesions with a lower FD, that required at least eight IVI
during the first year of treatments.
Repeatability Evaluation
The means of the different parameters
measured together with the ICC are listed in
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Figure 2. Treatment-naïve choroidal neovascularization (CNV) in AMD before and after intravitreal anti-VEGF injections. (Upper row) The
right eye of a 77-year-old male patient with type 2 CNV and a baseline visual acuity of 20/100. (Upper left) Optical coherence tomogra-
phy angiography (OCTA) image of the neovascular complex after automatic delineation. We observe a densely branched network (SA =
1.68 mm2, FD = 1.51) with tiny capillaries emanating from the center of the lesion and subretinal fluid in the structural B-scan OCT. (Upper
middle) Follow-up OCTA 4 weeks after the loading dose; the visual acuity was 20/60. We observe the pruning effect of anti-VEGF, with disap-
pearance of the tiny vessels, a voluminous central core vessel (SA= 0.13 mm2, FD= 1.31) and the absence of intraretinal fluids in structural
OCT. (Upper right) Follow-upOCTA 12months after the first treatment and after a total of 7 intravitreal injections given following a treat-and-
extendprotocol. The visual acuity improved to 20/40. In theOCTA,weobserve a regrowthof a branchingnetwork from the central core (SA=
1.71 mm2, FD = 1.54). In the structural OCT, we noticed a nasal growth of the CNV and a small lamella of subretinal fluid. (Lower row) The
left eye of a 79-year-old male patient with type 2 CNV and a baseline visual acuity of 20/125. (Lower left) OCTA of the neovascular complex
after automatic delineation. We observe a densely branched network with loops and tiny capillaries emanating from the center of the lesion
(SA = 4.65 mm2, FD = 1.53) and massive subfoveal fluid in the structural B-scan OCT. (Lower middle) Follow-up OCTA en face projection
4 weeks after the loading dose; the visual acuity was 20/63. We observe the pruning effect of anti-VEGF, with a disappearance of the tiny
vessels, the presence of a voluminous central core vessel, few anastomosed vessels (SA= 2.36mm2, FD= 1.44), and the absence of intrareti-
nal fluids in structural OCT. (Lower right) Follow-up OCTA 12months after the first treatment and after a total of 6 intravitreal injections given
following a treat-and-extend protocol. The visual acuity remained 20/63. In the OCT-A, we observe the regrowth of tiny vessels from the
central core with an expansion of the CNV surface area (SA = 3.94 mm2, FD = 1.54). In the structural OCT, we notice the development of
subretinal fibrosis with erosion of the outer retinal layer architecture.
Figure 3. Partial function showing the functional form of the association between the BCVA difference after loading dose (x-axis) and the
odds of a gain of at least 5 ETDRS letters at 12 months (y-axis). The solid curve represents the estimate of this functional form; the dashed
curves represent the lower and upper limits of the 95% confidence intervals estimated for each BCVA difference after the loading dose.
Positive values on the y-axis mean higher odds of a good functional outcome (gain of at least 5 ETDRS letters) at 12 months.
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Table 2. OCT-A Parameters at Different Follow-Up Evaluations
Baseline 3 M* P† 12M P‡
FD 1.49 (1.40-1.55) 1.44 (1.25-1.53) <0.001 1.47 (1.37-1.54) 0.198
LAC 0.29 (0.26-0.34) 0.29 (0.26-0.33) 0.669 0.32 (0.27-0.35) 0.126
SA 0.62 (0.28-1.52) 0.47 (0.14-1.43) 0.006 0.92 (0.35-2.08) 0.757
VD 0.55 (0.49-0.67) 0.50 (0.42-0.60) 0.062 0.53 (0.44-0.61) 0.092
Results are presented as median (interquartile range).
*One month after the last of 3 monthly injections.
†P value for the comparison of baseline and 3-month values (n = 64).
‡P value for the comparison of baseline and 12-month values (n = 52). M = months.
Figure 4. Partial functions showing the functional formof the associationbetween thebaseline FD (x-axis, A) or baseline bloodflow surface
area (x axis, B) and the treatment burden (y-axis). The solid curve represents the estimate of this functional form, the dashed curves represent
the lower and upper limits of the 95% confidence intervals estimated for each FD unit (A) or baseline blood flow surface area (B). Positive
values in the y-axis mean higher odds of a high treatment burden (defined as at least 8 IVI in the first year of treatments).
Supplementary Table S8. ICC for all the parame-
ters analyzed were above 0.90.
Discussion
In this study, with an attempt of a novel approach,
used OCTA to monitor quantitative flow changes in
treatment-naïve CNV during 1 year of anti-VEGF
treatment under a TAE regimen. The branching
complexity and blood flow area decrease immediately
after the loading dose and return to the original size at
12months.We highlighted several quantitative features
of CNV blood flow before the anti-VEGF treatment
that might be discriminative of the number of IVIs in
the first year of a TAE regimen.
Previous qualitative assessments of OCT-A images
in CNV networks showed that most of the lesions
demonstrated shrinkage of fine peripheral vessels and
arteriogenesis of the remaining vessels after anti-
VEGF treatment.22 Coscas et al. found an area reduc-
tion in mixed type 1 and 2 neovascularization after
4 weeks of VEGF trap treatment.23 More recently,
other studies have studied FD and LAC as potential
quantitative biomarkers to characterize CNV branch-
ing complexity and heterogeneity, respectively.11–13
FD quantifies the variations in space filling using
the box-counting method and provides a way of
characterizing branching in terms of complexity. In
two-dimensional images, FD attains a value between
zero and two with higher values indicating increased
pattern complexity. Previous works demonstrated that
FD varies according to the number of secondary
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Figure 5. Treatment-naïve CNV in AMD with a low treatment burden of intravitreal anti-VEGF injections. (Upper row) The left eye of an 81-
year-old male patient with type 1 CNV and a baseline visual acuity of 20/25. (Upper left) OCT-A of the neovascular complex after automatic
delineation.Weobserve amediumsizedbranchedandorganizednetwork (SA=1.14mm2, FD=1.51) andpigment epitheliumdetachments
(PED) with subretinal fluid in the structural B-scan OCT. (Upper middle) Follow-up OCT-A en face projection 4 weeks after the loading dose,
the visual acuity remained stable (20/25). We observe a reduction of blood flow area and of the branching pattern, only central vessels
remain (SA= 0.77mm2, FD= 1.32) and there is an absence of fluids in structural OCT. (Upper right) Follow-upOCT-A 12months after the first
treatment and after a total of 7 intravitreal injections given following a treat-and-extend protocol. The visual acuity remained stable (20/25).
In the OCT-A blood flow, we observed a growth of the CNV and an organized and branched network around two main trunks (SA = 2.33
mm2, FD = 1.57). In the structural OCT, we noticed a reduction of the height with an increase of the extension of the PED and an absence
of subretinal fluid. (Lower row) The left eye of a 66-year-old female patient with type 1 CNV and a baseline visual acuity of 20/40. (Upper left)
OCT-A image of the neovascular complex after automatic delineation. We observed an organized branched network of anastomosed linear
capillaries (SA = 0.63 mm2, FD = 1.48) and subretinal fluid in the structural B-scan OCT. (Upper middle) Follow-up OCT-A 4 weeks after the
loading dose; visual acuity improved to 20/20. Blood flow aspect remains unchanged (SA = 0.67 mm2, FD = 1.48) and we observed the
persistence of a small lamella of subretinal fluid in structural OCT. (Upper right) Follow-up OCTA 12months after the first treatment and after
a total of 6 intravitreal injections given following a treat-and-extend protocol. The visual acuity remained 20/20. In the OCT-A, we observed
a small increase in SA and branching complexity of the CNV blood flow (SA= 0.82mm2, FD= 1.49) and the persistence of a residual lamella
of subretinal fluid in structural OCT.
divisions of the CNV: the higher the number of
discernible secondary divisions, the higher the FD
value.11,12 Al-Sheik et al. evaluated eyes with non-
naïve active CNV and qualitative features of angio-
genesis following one anti-VEGF IVI. They found
attenuation and pruning of secondary ramifications
in en-face OCTA, with subsequent reduction of the
FD.11 Our results are consistent with this observation
showing a significant decrease of FD after a loading
dose of three monthly anti-VEGF treatments (Fig. 2).
We also demonstrated that the relative difference of
FD after the loading dose had a weak discriminative
ability regarding the response to anti-VEGF, assessed
by retinal fluids evaluation. On a cohort of 36 eyes,
Coscas et al. showed a high rate (33.3%) of false-
positive qualitative evaluations on OCT-A (i.e., poten-
tially active CNV according to the presence of OCT-A
criteria but without retinal fluids according to the OCT
B-scan).8 Our results agree with this notion of a weak
association between blood flow aspect and retinal fluid
and suggest that factors other than CNV morphol-
ogy are responsible for retinal exudation. Regarding
the visual acuity at 12 months’ follow-up, FD did not
differ between good and bad responders.Moreover, the
corresponding GLM models attained a weak discrim-
inative ability to identify patients that had a gain of
at least five ETDRS letters of BCVA. The present
analysis disclosed that only the BCVA difference after
the loading dose and baseline had a good discrimina-
tive ability. This agrees with a recent subanalysis of
the HARBOR clinical trial spectral domain structural
OCT-B scan data performed by Schmidt-Erfurth et
al.24 Using machine learning, the authors found that
functional outcomes were determined by BCVA levels
during the loading dose with aminor influence of fluid-
related features. Our analysis shows a poor association
between the most studied quantitative OCTA param-
eters and functional outcomes. Concerning the treat-
ment burden, baseline FD had an inverse association
with the number of IVI and the respective model had a
good discriminative ability to distinguish patients that
had seven or less IVI in the first year of a TAEprotocol.
Lacunarity is a measure of the size of gaps within
a structure and enable to characterize the texture of
vascular networks.18 Higher values reflect inhomo-
geneity and lower values reflect a more homoge-
nous vascular structure. Therefore, we would expect
naive CNV membranes to show higher lacunarity
values after the anti-VEGF treatments. However, our
results showed consistently nonsignificant lacunarity
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Figure 6. Treatment naïve CNV in AMDwith a high treatment burden of intravitreal anti-VEGF injections. (Upper row) The left eye of an 82-
year-old male patient with type 1 CNV and a baseline visual acuity of 20/25. (Upper left) OCT-A of the neovascular complex after automatic
delineation. We observed a small, densely branched and disorganized network (SA = 0.15 mm2, FD = 1.24) and small pigment epithelium
detachments (PED) with subretinal fluid in the structural B-scan OCT. (Upper middle) Follow-up OCTA en face projection 4 weeks after the
loading dose; visual acuity remained 20/25.Weobserved a circumferential growth of the lesionwith reorganization of the blood flowaround
a central core vessel (SA = 0.26 mm2, FD = 1.51) and the absence of fluids in structural OCT. (Upper right) Follow-up OCT-A 12 months after
the first treatment and after a total of 11 intravitreal injections given following a treat-and-extend protocol. The visual acuity has dropped
to 20/40. In the OCT-A, we observed the definition of a central core vessel with tiny capillaries emanating toward the nasal half of the lesion
(SA= 0.44mm2, FD= 1.48). In the structural OCT, we noticed an increase of the extension of a fibrovascular PED and subretinal fluid. (Lower
row) The left eye of an 84-year-old male patient with type 2 CNV and a baseline visual acuity of 20/63. (Lower left) OCT-A of the neovascular
complex after automatic delineation. We observed a small and densely branched network with small vessels emanating from a central core
lesion (SA = 0.48 mm2, FD = 1.35) and intraretinal cysts in the structural B-scan OCT. (Lower middle) Follow-up OCT-A en face projection 4
weeks after the loading dosewith visual acuity of 20/32.We observed a circumferential growth of the lesion, a densely anastomotic network
(SA= 2.32mm2, FD= 1.60) and the absence of fluids in structural OCT. (Lower right) Follow-upOCT-A 12months after the first treatment and
after a total of 10 intravitreal injections given following a treat-and-extend protocol. The visual acuity has dropped to 20/63. In the OCT-A,
we observe the organization of the blood flow aspect with anastomotic loops in the nasal half and linear capillaries in the temporal half of
the lesion (SA = 2.66 mm2, FD = 1.56). In the structural OCT, we noticed an increase of the height of the fibrovascular PED, hyperreflective
intraretinal dots above the PED, and the absence of retinal fluids.
differences over the follow-up visits. Roberts et al. have
studied patients under treatment for active nAMDwith
a median of 34 anti-VEGF injections before study
inclusion and compared lacunarity between good and
poor responders to anti-VEGF.13 The authors have
also shown nonsignificant differences and hypothesized
that the lack of differences was the result of a previ-
ous “normalization” of the CNV vasculature by anti-
VEGF. In our study, this limitation was overcome by
enrolling only treatment-naïve patients. Our findings
support the hypothesis that lacunas of the vascular
skeleton do not change their arrangement after anti-
VEGF, which makes lacunarity a nonrelevant OCT-A
parameter for nAMD follow-up.
Blood flow area is a readily available and well-
studied OCT-A parameter. Previous studies have
shown that OCT-A is able to show the minimal CNV
surface25 and is reproducible for accurate evaluation
of CNV blood flow area.26 Miere et al. have recently
demonstrated a reduction in CNV surface area in
treatment-naïve eyes after the loading dose of three
monthly IVI of anti-VEGF.27 Our results agree with
these findings, as we demonstrated a blood flow area
reduction after the loading dose. However, consis-
tent data about the relative modification of flow area
during the follow-up of the disease are scarce as most
of previous studies had variable follow-up intervals
and flexible treatment protocols.6,28 McClintic et al.
were the first group to prospectively evaluate a cohort
of patients followed over a strict as-needed regimen
for 12 months. They verified a significant decrease
of CNV blood flow area after the first treatments
followed by a regrowth of the lesion. The relative
change from baseline was statistically nonsignificant
and growth occurred irrespective of retinal fluids in
structural OCT.9 We verified the same modifications of
blood flow area in patients followed under a treat-and-
extend regimen. We corroborate the notion that CNVs
grow during anti-VEGF treatments. This process had
been previously hypothesized by Spaide as “vascular
abnormalization.” According to this hypothesis, CNV
grow because of unimpeded arteriogenesis in the face
of periodic pruning of angiogenic vascular sprouts
by VEGF withdrawal.22 We have studied whether the
relative modifications of surface area could be associ-
ated with clinical outcomes. We verified that the ability
to distinguish patients with a gain of at least five
ETDRS letters in the first year was consistently weak.
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Although we agree with the notion of vascular “abnor-
malization,” blood flow area seems to have a minor
association with functional outcomes, highlighting the
need to assess other parameters. Finally, we verified
that baseline blood flow area had an inverse associa-
tion with the number of IVI and a good discrimina-
tive ability to distinguish patients that had seven or less
IVI in the first year of a TAE protocol, an association
that we have also observed concerning baseline FD.
Analyzed together, our results indicate that patients
with a lower baseline FD and a lower surface area have
higher odds of having eight or more IVI in the first
year of a treat-and-extend protocol. While speculative,
we hypothesize that this finding reflects the impact of
distinct angiogenic environments in CNVmorphology.
In the presence of high VEGF levels, CNVswould have
numerous tiny branches and a disorganized architec-
ture, reflecting an aggressive angiogenic process with
greater exudation and a heavier treatment burden. In
eyes with lower VEGF availability, CNV would grow
without leakage maturing their branching architecture
toward a tangled network before exudation becomes
overly symptomatic. Figure 4 depicts typical examples
of patients that required less than eight IVI in the
first year of treatment; we observed large and complex
lesions. On the other hand, Figure 5 depicts typical
examples of patients that required more than eight
IVI in the first year of treatments: we observed small
CNVs with a disorganized architecture. According to
our hypothesis, there could be a structural-functional
relationship between CNV morphology and treatment
burden: eyes with lower VEGF production would need
less IVI to control the exudative features and the
opposite in eyes with higher VEGF production.
Strengths of our study include the use of an
automatic image analysis protocol with excellent repro-
ducibility results, enrollment of naïve nAMD patients,
and a uniform follow-up evaluation of patients treated
according to a treat-and-extend protocol on a real-life
setting.
Limitations include a small sample size and techni-
cal limitations inherent to the current technology. By
conducting a real-world study, 25% of patients were
lost to follow-up, giving rise to a selection bias as
only the compliant patients remained in the study. This
rate of lost on follow-up is similar to other real-life
cohorts29 and was mostly related to patients’ prefer-
ence to perform treatments closer to their residence.
We acknowledge that including the first eye diagnosed
with nAMD per patient might have left out very early
presenters. The replication of our findings in very early
presenters could be evaluated in future works. We also
acknowledge that PED height is associated with signal
loss in OCTA.30 Selecting patients with PED inferior
to 250 μmmight have excluded patients in which blood
flow was not detectable with OCTA, limiting the appli-
cation of our results to nAMD patients in which blood
flow is readily detected by OCTA.We are also aware of
the importance of structural OCT outer retina modifi-
cations in response to anti-VEGF. Further studies may
evaluate the association between OCT-A parameters,
structural OCT changes and functional response. A
larger sample size will certainly yield more statistical
power to uncover other relationships not identified in
the present study.
In conclusion, all the OCTA parameters evalu-
ated were a poor biomarker in predicting anatomic
and functional response. Baseline FD and SA were
the best biomarkers regarding treatment burden. It
appears useful to include baseline FD analysis and
blood flow area evaluation in future studies because
they seem to be associated with a distinct number
of anti-VEGF injections in the first year of disease
management.
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